Introduction: Antipsychotic medications are commonly prescribed off-label in acutely ill patients for non-psychiatric clinical indications such as delirium or insomnia. New prescription initiation of antipsychotics in acute care settings increases the proportion of patients discharged home on antipsychotics without approved clinical indication. Long-term use of antipsychotics is associated with increased risk of sudden cardiac death, falls and cognitive impairment. An understanding of acute care off-label antipsychotic prescribing practices and healthcare professional, patient and family perceptions related to antipsychotic prescribing and deprescribing is necessary to facilitate in-hospital deprescribing initiatives.

Methods And Analysis: We present the protocol for a scoping review following the methodology proposed by Arksey and O'Malley and the Scoping Review Methods Manual by the Joanna Briggs Institute. We will search five databases including MEDLINE, EMBASE, CINAHL, PsycINFO and Web of Science from inception to 3 July 2021 (ie, planned search date). We will include both peer-reviewed and non-peer-reviewed qualitative and quantitative studies to identify antipsychotic prescribing practices, and to describe healthcare professional, patient and family perceptions towards antipsychotic prescribing and deprescribing in the acute care setting. Protocols, systematic and scoping reviews will be excluded. Two reviewers will calibrate and perform study screening and data abstraction for quantitative and qualitative outcomes of eligible studies. Quantitative outcomes will include study identifiers, demographics and descriptive statistics of antipsychotic prescribing practices. Qualitative synthesis describing perceptions on antipsychotic prescribing practices will include deductive thematic analysis with mapping of themes to the domains of the Theoretical Domains Framework, a 14-domain behaviour and behaviour change framework.

Ethics And Dissemination: No ethical approval will be required for this study as only data from published studies in which informed consent was obtained by primary investigators will be retrieved and analysed. The results of this scoping review will inform integrated knowledge translation initiatives aimed at in-hospital antipsychotic medication deprescribing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244676PMC
http://dx.doi.org/10.1136/bmjopen-2021-057585DOI Listing

Publication Analysis

Top Keywords

antipsychotic prescribing
32
prescribing practices
20
perceptions antipsychotic
16
acute care
16
scoping review
16
patient family
12
healthcare professional
12
will include
12
antipsychotic
10
will
9

Similar Publications

Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.

Neurol Ther

January 2025

Health Economics and Outcomes Research, Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, CA, 92130, USA.

Introduction: Chorea is the primary manifestation of Huntington's disease. Different clinicians pursue varied approaches to chorea management, and real-world evidence describing them is needed. The objective of this study was to assess the presence and severity of chorea, chorea pharmacotherapy, and treatment practice, and patterns in a large natural-history cohort with Huntington's disease.

View Article and Find Full Text PDF

Characterizing Difficulties and Management of Sleep Disturbances in a Tertiary Palliative Care Unit-A Retrospective Review.

J Palliat Care

January 2025

Departments of Internal Medicine and Family Medicine, Section of Palliative Care Medicine, University of Manitoba, Winnipeg, Canada.

Difficulty sleeping is common in palliative care, however often unrecognized by palliative care physicians. This retrospective review aims to gain a better understanding of the causes and treatment of sleeping disturbances in a tertiary palliative care unit. This study included 200 palliative care inpatients admitted between January 1, 2015, and August 31, 2020.

View Article and Find Full Text PDF

Quetiapine is associated with pancreatitis: A real-world pharmacovigilance study.

J Affect Disord

January 2025

Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Electronic address:

Quetiapine, an atypical antipsychotic widely prescribed for conditions including schizophrenia and bipolar disorder has been associated with a potential risk of pancreatitis. This study aimed to quantify the association between quetiapine use and the occurrence of pancreatitis using data from the FDA Adverse Events Reporting System. Disproportionality analyses were conducted to evaluate the frequency of pancreatitis reports linked to quetiapine compared to other drugs in the FAERS database.

View Article and Find Full Text PDF

Antipsychotic off-label use in the 21st century: An enduring public health concern.

Dialogues Clin Neurosci

December 2025

University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France.

Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms.

View Article and Find Full Text PDF

Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia.

Drug Metab Pharmacokinet

November 2024

Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:

The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!